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ABSTRACT
Sterol regulatory element binding protein-1c
(SREBP-1c) is a basic helix–loop–helix (bHLH) homo-
dimeric transactivator, which induces itself and sev-
eral lipogenic enzymes, notably fatty acid synthase
(FAS). We demonstrated that hypoxia-inducible
factor (HIF) represses the SREBP-1c gene by
inducing Stimulated with retinoic acid (Stra)13/
Differentiated embryo chondrocyte 1(DEC1) and its
isoform, DEC2. Stra13/DEC1 and DEC2 are bHLH
homodimeric transcription repressors. We found
thatbothStra13andDEC2inhibitSREBP-1c-induced
transcription by competing with SREBP-1c for bind-
ing to the E-box in the SREBP-1c promoter and/or by
interacting with SREBP-1c protein. DEC2 is instantly
and temporarily induced in acute hypoxia, while
Stra13 is induced in prolonged hypoxia. This expres-
sion profile reflects the finding that Stra13 represses
DEC2, thus maintains low level of DEC2 in prolonged
hypoxia. DEC2-siRNA restores the hypoxic repres-
sion but Stra13-siRNA fails to do so, suggesting
that DEC2 is the major initiator of hypoxic repression
of SREBP-1c, whereas Stra13 substitutes for DEC2
in prolonged hypoxia. Our findings imply that
Stra13 and DEC2 are the mediators to repress
SREBP-1c gene in response to hypoxia. By doing
so, HIF and its targets, Stra13 and DEC2 reduce
the ATP consuming anabolic lipogenesis prior to
the actual decrease of ATP acting as a feed-forward
mechanism.
INTRODUCTION
Under hypoxic conditions, cells cannot maintain the
aerobic respiration that is required for oxidative phos-
phorylation by mitochondria, and this leads to decreased
generation of ATP. Many types of hypoxia-tolerant cells
avoid the risk of energy failure not only by increasing
anaerobic glycolysis, but also by decreasing
O2 consumption (1). The hypoxia-inducible factor-a/b
(HIF-a/b) heterodimeric transcription factor plays a
central role in both processes. HIF represses the respira-
tion and biogenesis of mitochondria by inducing pyruvate
dehydrogenase kinase 1 and the c-Myc antagonist, MXI-1,
respectively (2–4).
The HIF-a and b subunits belong to the basic helix–
loop–helix (bHLH)-Per-Arnt-Sim (PAS) protein family.
In normoxia, HIF-a is ubiquitinated and rapidly
degraded. It contains a binding site for the ubiquitin E3
ligase, von Hippel-Lindau protein (pVHL), which ubiqui-
tinates it, targeting it for degradation. pVHL recognizes
and binds to hydroxylated proline residues in HIF-a.
Proline hydroxylation of HIF-a is catalyzed by HIF-a-
speciﬁc proline hydroxylases, using O2, a-ketoglutarate,
Vitamin C and Fe
2þ (5). Another HIF-a-speciﬁc aspara-
ginyl hydroxylase named factor-inhibiting HIF-1a uses
the same cofactors to inhibit the transactivation activity
of HIF-1a. Therefore, in addition to hypoxia, HIF-a can
be stabilized and transactivated by other factors that inhi-
bit these hydroxylation reactions, such as divalent metals,
oxidizing agents, succinate and an increased oxygen con-
sumption rate of mitochondria (3,4).
HIF-1a was the original HIF-a isoform identiﬁed by
aﬃnity puriﬁcation, while HIF-2a/EPAS-1 was identiﬁed
in a homology search (6). Both HIF-1a and HIF-2a form
functional heterodimers with HIF-1b, also referred as
aryl hydrocarbon receptor nuclear translocator (Arnt).
Although knockout mice experiments showed that
HIF-1a and 2a have distinctly diﬀerent functions and
play nonredundant roles (7), no target genes speciﬁc for
HIF-2a have been identiﬁed. HIF-1a and HIF-2a share
many target genes, but HIF-1a appears to be the predomi-
nant form responsible for induction of the target genes (8).
There is some evidence that a decreased demand
for ATP is also important for hypoxic adaptation.
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is suppressed rapidly, thereby decreasing the consumption
of ATP (9). Another ATP-consuming anabolic process is
lipogenesis, which encompasses the processes by which
glucose is converted to triglyceride by lipogenic enzymes,
and takes place in both liver and adipose tissue (10). Fatty
acid synthase (FAS), the key lipogenic enzyme responsible
for the endogenous synthesis of fatty acids, has been
shown to be regulated by hormonal and nutritional eﬀects
at the levels of transcription and activity (11,12). Insulin
and sterols also have long-term eﬀects on the expression
of FAS genes (13), probably via the transcription
factor, sterol regulatory element binding protein-1c
(SREBP-1c), also referred to as adipocyte determination,
and diﬀerentiation-dependent factor 1 (ADD1) (14). The
SREBP-1 gene encodes two almost identical proteins,
SREBP-1a and SREBP-1c transcripts from two diﬀerent
promoters. Besides the ﬁrst four unique amino acids,
SREBP-1c is identical to SREBP-1a (15). In the mouse
liver, the SREBP-1c is 9-fold more than SREBP-1a. The
SREBP-1c protein retains a greater ability to stimulate
transcription of genes involved in fatty acid synthesis
while SREBP-1a for cholesterol metabolism (15).
SREBP-1c promoter contains a sterol regulatory element
(SRE) and can be induced by SREBP-1c itself. Therefore,
the SREBP-1c promoter makes it possible to form a posi-
tive feedback loop expression of SREBP-1c (16,17).
SREBP-1c/ADD1 belongs to the bHLH leucine zipper
family, and is synthesized as a 125-kDa precursor protein
bound to the endoplasmic reticulum (ER). When it is
cleaved during sterol deprivation, its N-terminal region
(amino acids 1–480) is released from the ER membrane
into the nucleus as a 68-kDa mature transcription factor.
The active SREBP-1c makes homodimer, which has dual
DNA-binding speciﬁcity; it binds not only to the SRE,
but also to the E-box (14). Besides being regulated by
proteolytic release, transcription of the SREBP-1c gene
is regulated by many hormonal and nutritional signals,
including fasting and re-feeding (18), and insulin (19).
SREBP-1s are known to contribute the adipogenesis by
promoting that synthesis of the endogenous ligands
for the adipogenic transactivator PPARg. Yun et al. (20)
showed that Stra13, a hypoxia-induced transcription
repressor family, represses PPARg2 promoter and func-
tions as a mediator of hypoxic inhibition of adipogenesis.
Stra13 is also referred to as Diﬀerentiated embryo
chondrocyte 1 (DEC1). Stra13/DEC1 and its isoform
DEC2 are class B type bHLH proteins which make homo-
dimer. Both Stra13 homodimer and DEC2 homodimer are
able to bind the E-box sequences (21). Stra13/DEC1 and
DEC2 homodimers play a key role in cell diﬀerentiation,
circadian rhythms, immune regulation and carcinogenesis
(22). In the current study we investigated how HIF and its
targets, Stra13/DEC1 and DEC2 bring about hypoxic
repression of FAS and SREBP-1c.
MATERIALS AND METHODS
Materials and plasmids
The anti-HIF-1a antibody was obtained from Novus
Biochemicals. The anti-HIF-1b/Arnt antibody and
anti-human-SREBP-1 antibody were purchased from BD
Biosciences (Palo Alto, CA, USA) and Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Anti-mouse-
SREBP-1 antibody was also generated, as described pre-
viously (23). The following cDNAs were used: HIF-1a
(human, U22431), HIF-1b (human, NM_001668),
Stra13/DEC1 (mouse, AF010305), DEC2 (mouse,
NM_024469) and SREBP-1c (amino acids 1–403 of rat
AF286469). The plasmid pEBG-SREBP-1c encodes rat
SREBP-1c (amino acid 1–403) fused to Glutathione-
S-transferase (GST) under the control of the mammalian
elongation factor 1 promoter. The FAS promoter-driven
luciferase reporter plasmid contains the upstream regula-
tory region ( 220bp to þ25bp) of the rat FAS promoter
(24). The SREBP-1c promoter-driven luciferase reporter
plasmid contains the enhancer and promoter region
( 2.7kb to þ1bp) of the mouse SREBP-1c gene (23).
All chemicals were purchased from Sigma Co.
Measurementof ATP
A constant-light signal luciferase assay developed by
Boehringer-Mannheim (ATP Bioluminescence Assay Kit
CLS II) was utilized to determine levels of ATP. Wild-type
mouse Hepa1c1c7 cells were plated in triplicate at 5 10
4
cells in a 35-mm tissue culture plate and allowed to incu-
bate overnight. After 16h, the cells were exposed to
hypoxia for the indicated times. Molar amounts of ATP
were determined using ATP standards (10
–4 to 10
–11M
ATP) versus the relative luciferase units. Luciferase units
were normalized for total protein concentration as deter-
mined by the Bradford assay using bovine serum albumin
as a standard. We present the averages and standard
deviations of at least three experiments.
Northern analysis and quantitative real-time reverse
transcription (RT)–polymerase chain reaction
(PCR) (Q-PCR)
Total RNA was isolated using an RNeasy spin column
(Qiagen Inc., Valencia, CA, USA). Northern analyses
were performed as described previously (25). cDNA was
reverse transcribed from total RNA (1mg) using AMV
reverse transcriptase with dNTPs and random primers
(Promega, Madison, WI, USA). For quantitative real
time reverse transcription (RT)–polymerase chain reaction
(PCR) (Q-PCR) analysis, the iQ
TM SYBR Green Supermix
and MyiQ single color real-time PCR detection system
(Bio-Rad, Hercules, CA, USA) were used. The expression
level of 18S rRNA was used for normalization. All PCRs
were performed in triplicate. We present the average and
standard deviation of at least three experiments. Primer
sequences are given in Supplementary Table S1.
Electrophoretic mobility shift assays (EMSA)
GST-SREBP-1c (amino acids 1–403) fusion protein was
expressed in Escherichia coli (BL21) and puriﬁed using
glutathione uniﬂow resin according to the instruction of
manufacturer (Amersham Biosciences, Uppsala, Sweden).
The oligonucleotides used for the E-box-containing FAS
promoter ( 74 to  51bp); the oligonucleotides used
for the SRE complex sequences of SREBP-1c promoter
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mutant sequences are shown in Figure 5B and
Supplementary Figure S2C. Each pair of oligonucleotides
(1.75 pmol) was annealed and labeled with a-[
32P]-dATP
and Klenow enzyme. Recombinant GST-SREBP-1c
(amino acids 1–403) protein were preincubated with poly-
deoxyinosinic-deoxycytidylic acid (1mg) in 20ml binding
reactions containing reaction buﬀer [10mM Tris pH 7.5,
50mM KCl, 2.5mM MgCl2, 0.05mM EDTA, 0.1% (v/v)
Triton X-100, 8% (v/v) glycerol, 1mM dithiothreitol and
0.1%(w/v) non-fat dry milk] for 30minon ice, as described
(26). The radiolabeled oligonucleotides (4 10
5c.p.m.,
approximately 0.3 pmol) were incubated with recombinant
GST-SREBP-1c protein (5mg) for 45min on ice, and reac-
tionmixtures were thenseparated by6% PAGE at 48C and
exposed to X-ray ﬁlm.
Co-immunoprecipitation and GST pull-down
Human 293 cells were transfected with pEBG-SREBP-1c
together with either pCMV-myc-Stra13, pCMV-myc-
DEC2 or pCMV-3ﬂag-HIF-1a and whole-cell extracts
were prepared. For immunoprecipitation, 300mg samples
of whole-cell lysates were analyzed as described (25). The
cleared extracts were mixed and precipitated with 2mgo f
the indicated antibody.
[
35S]-labeled SREBP-1c, HIF-1a, HIF-1b or Stra13 pro-
teins were in vitro translated using a rabbit reticulocyte
lysate (Promega), then incubated for 2h at 48C with
immobilized GST or GST-SREBP-1c in 500ml of NETN
buﬀer [20mM Tris (pH 8.0), 100mM NaCl, 1mM EDTA,
0.5% NP-40 and 1mM PMSF]. GST-SREBP-1c (amino
acids 1–403) bound to the glutathione-uniﬂow resin was
washed three times with 1ml of NETN buﬀer at 48C and
eluted by boiling in SDS sample buﬀer. Boiled samples
were subjected to SDS–PAGE and autoradiography.
Gene silencing using small interfering RNA (siRNA)
siRNAs speciﬁc for HIF-1a, HIF-2a, Stra13, DEC2 and
green ﬂuorescent protein (GFP) were synthesized by
Samchully Pharm. Co. (Seoul, Korea). Sequence of each
siRNA is shown in Supplementary Table S1. For siRNA
transfection, Hepa1c1c7 cells or 3T3-L1 cells were plated
at 5 10
5 cells in a 60-mm plate. Eighteen hours later,
transfection was carried out using PolyMAG according
to the instructions of the manufacturer (Chemicell
GmBH, Germany). Forty-eight to 72 hours after transfec-
tion, total RNA or whole-cell extracts were prepared for
further assays. To generate stably HIF-1a knockdown
cells, we used a retroviral vector system. We ligated a
short-hairpin RNA (shRNA) against HIF-1a into
pSIREN-RetroQ vector (BD Biosciences) to generate
pSIREN-RetroQ-shHIF-1a, according to the instructions
of the manufacturer (BD Biosciences). pSIREN-RetroQ-
shcontrol were provided from BD Biosciences. Sequence
of each shRNA is shown in Supplementary Table S2.
Chromatin immunoprecipitation (ChIP) assay
Human 293 cells were transfected with pEBG-SREBP-1c
together with pCMV-myc-Stra13, pCMV-myc-DEC2
or pCMV-3ﬂag-HIF-1a/pcDNA3-HIF-1b (Arnt). ChIP
assays were performed according to the instructions of
the manufacturer (Upstate Biotechnology, Lake Placid,
NY, USA). The transfected cells were cross-linked in
1% formaldehyde at 378C for 10min and resuspended in
200ml of lysis buﬀer [1% SDS, 10mM EDTA, 50mM
Tris–HCl (pH 8.1)]. Lysates were sonicated. We measured
OD 260 of the sonicated lysate solution to ensure that the
amount of chromatin used in each sample is similar (27).
Then we diluted the sonicated lysate 10-fold with ChIP
dilution buﬀer [0.01% SDS, 1.1% Triton X-100, 1.2mM
EDTA, 16.7mM Tris–HCl (pH 8.1), 167mM NaCl].
The diluted lysates were immunoprecipitated with 2mg
of anti-GST antibody (Upstate Biotechnology), anti-ﬂag
antibody (Sigma) or anti-myc antibody (clone 9E10,
Boehringer Mannheim). The immunoprecipitates were
washed with four kinds of buﬀers; low salt buﬀer, high
salt buﬀer, LiCl wash buﬀer and TE buﬀer as described
(23). The immune complexes were eluted with 300mlo f
elution buﬀer (1% SDS, 0.1M NaHCO3) and reversed
(23). The isolated DNAs were used for PCR and the
primers are shown in Supplementary Table S3.
Transient transfection andluciferase assay
Cells were plated at 1 10
5 cells/well in 24-well plates.
Eighteen hours later, transfection was carried out using
Lipofectamine plus reagent (Invitrogen, Carlsbad, CA,
USA). Forty-eight hours after transfection, cell extracts
were prepared and analyzed with a luminometer (Turner
TD-20/20, Promega) using the luciferase assay system
(Promega). Luciferase activity was normalized for total pro-
tein concentration as determined by the Bradford assay
using bovine serum albumin as a standard. The transfection
eﬃciency was monitored by measuring b-galactosidase
activity of the cotransfected b-galactosidase-encoding
plasmid (pCHO110).
RESULTS
Hypoxia reduces theexpression ofFAS and SREBP-1c
In adipocytes, the exposure of hypoxia reduces the content
of triglyceride and cholesterol (Supplementary Figure S1A
and B) (28–31). To determine whether hypoxia inﬂuences
the expression of the lipogenic enzymes, we measured FAS
mRNA. Hypoxia reduced FAS mRNA in Hep3B human
hepatocytes, L6 mouse skeletal myocytes, C2C12 mouse
myoblasts, 3T3-L1 mouse preadipocytes and Hepa1c1c7
mouse hepatoma cells (Figure 1A). In contrast, transcripts
of hypoxia-inducible genes such as phosphoglycerate
kinase-1 (PGK-1) and glyceraldehydes-3-phosphate
dehydrogenase (GAPDH) increased. After 16h of hypoxic
exposure, FAS mRNA was reduced by 20% in Hepa1c1c7
cells (Figure 1B) but the ATP level was unaﬀected
(Figure 1C) (32,33). These ﬁndings imply that cells can
shut down anabolic genes prior to an actual reduction of
ATP, ultimately by reducing the levels of anabolic
enzymes such as FAS. Lipogenic gene expression is pro-
moted by potent lipogenic activators such as SREBP-1c.
Quantitative real-time RT–PCR (Q-PCR) showed that
hypoxic treatment reduced SREBP-1c mRNA in human
6374 Nucleic Acids Research, 2008, Vol. 36, No. 20hepatoma Hep3B cells (Figure 1D). The amount of
SREBP-1 protein was also reduced (Figure 1E).
HIF isinvolved inhypoxic repression ofFAS and SREBP-1c
To test whether HIF is involved in this process, we mea-
sured transcript and protein levels of FAS and SREBP-1c
in wild-type mouse hepatoma Hepa1c1c7 cells and HIF-
1b-defective Hepa1c1c7 variant cells (Figure 2A and B)
(34). Hypoxia failed to reduce mRNA of either FAS
or SREBP-1c in the HIF-1b defective cells, indicating
that HIF-1b is required for their repression by hypoxia.
We also tested hypoxic repression of FAS mRNA and
SREBP-1c protein in HIF-1a knockdown 3T3-L1 cells
generated by infection with a retrovirus encoding
shRNA against HIF-1a. We conﬁrmed a speciﬁc reduc-
tion of protein and mRNA of HIF-1a by the cognate
shRNA in 3T3-L1 cells (Figure 2C), and hypoxic treat-
ment failed to repress FAS mRNA and SREBP-1c protein
in the HIF-1a-knockdown 3T3-L1 cells.
HIF-1a and 2a induce HRE-dependent expression of
same target genes with diﬀerent temporal patterns (35).
Small inhibitory RNAs (siRNAs) against HIF-1a and
HIF-2a were transfected into Hepa1c1c7 cells and we
conﬁrmed the speciﬁc reduction of HIF mRNA by the
cognate siRNAs (Figure 2D). We tested whether HIF-2a
is also involved in hypoxic repression of SREBP-1c
protein. Western analysis showed that HIF-1a siRNA
but not HIF-2a siRNA restored the expression of
SREBP-1c protein which was repressed by acute hypoxic
exposure (4h). In contrast, in prolonged hypoxia, both
HIF-1a siRNA and HIF-2a siRNA partially restored
the expression of SREBP-1c protein (Figure 2E) and
FAS (Supplementary Figure S1C). Taken together, our
ﬁndings demonstrate that HIF-1a and HIF-2a act on
SREBP-1c repression but in diﬀerent temporal windows,
with HIF-1a acting in the acute hypoxic phase and both
HIF-1a and-2a in the prolonged phage.
Stra13/DEC1isinvolvedinhypoxicrepressionofSREBP-1c
We investigated whether a transcription repressor, Stra13/
DEC1 is involved in HIF-dependent repression of
SREBP-1c. Northern analyses conﬁrmed that hypoxia
increases mRNA level of Stra13/DEC1 prior to maximum
decrease of FAS expression (Figures 3A and 1B). By using
HIF-1b defective cells, we conﬁrmed that Stra13 induction
was HIF-1-dependent (Figure 3B). Consistent with the
case of SREBP-1c, in acute (4h) hypoxic exposure,
siRNA against HIF-1a reduced the hypoxic induction of
Stra13, whereas in prolonged hypoxic exposure (24h)
HIF-2a siRNA was more eﬀective than HIF-1a siRNA
(Figure 3C) (35).
We measured SREBP-1c protein in human 293 cells
transfected with either HIF-1a or Stra13. The results,
shown in Figure 4A indicate that even in normoxic cells,
forced expression of either HIF-1a or Stra13 reduces
the amount of the endogenous SREBP-1c protein.
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Nucleic Acids Research, 2008, Vol. 36, No. 20 6375These results indicate that either HIF-1a or Stra13 is suf-
ﬁcient to mediate hypoxic repression of SREBP-1c. The
promoter of the mouse SREBP-1c gene contains two
binding sites for Liver X Receptor (LXR), a sterol regu-
latory element complex ( 84 to  53 in the mouse
SREBP-1c gene) which consists of an E-box and SRE,
and recognition sites for nuclear factor-Y (NF-Y) and
Sp1 (Supplementary Figure S2A) (16,36). We transiently
cotransfected a plasmid encoding SREBP-1c cDNA
together with a reporter plasmid driven by the upstream
regulatory region ( 2700 to þ1) of the mouse SREBP-1c
gene. Since SREBP-1c transactivates its own promoter,
overexpression of SREBP-1c increased the activity of
SREBP-1c promoter (Figure 4B) (14,16). Even in the
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6376 Nucleic Acids Research, 2008, Vol. 36, No. 20presence of excess SREBP-1c, hypoxia reduced SREBP-1c
promoter activity. Cotransfection of either HIF-1a or
Stra13 reduced SREBP-1c promoter activity even in nor-
moxic cells (Figure 4B). Again, these results indicated that
HIF-1a and Stra13 repress the activity of SREBP-1c pro-
moter not only by reducing the amount of SREBP-1c, but
also by reducing its activity. We also found that HIF-1a
and Stra13 repress the activity of FAS promoter (Supple-
mentary Figure S2B). In order to test whether HIF-1a and
Stra13 interact with SREBP-1c, thereby preventing its
activity, we used bacteria-expressed GST-SREBP-1c
(amino acids 1–403) fusion protein and [
35S]-labeled
HIF-1a, HIF-1b, and Stra13 in GST pull-down assays.
The results, shown in Figure 4C, indicate that SREBP-
1c interacts with itself as a homodimer (23), that it inter-
acts with Stra13 as strongly as it does with itself, that it
also interacts with HIF-1a, though to a lesser degree, and
that HIF-1b fails to interact with SREBP-1c. ChIP assays
conﬁrmed that SREBP-1c interacts with Stra13 in vivo,
but scarcely with HIF-1a (Figure 4D). Our results suggest
that HIF-1a induces Stra13, and then Stra13 interacts
with SREBP-1c.
Interactions between bHLH proteins and SREBP-1c
promoter
Next, we investigated whether either HIF-1a or Stra13
inhibits DNA binding by SREBP-1c, since each has a
bHLH domain required for dimerization-dependent bind-
ing to the E-box motif (-CANNTG-). The SREBP-1c
proximal promoter contains the SRE complex, which
contains SRE (-ATCACCCCAC-), E-box and cis-
acting elements for NF-Y and Sp1 (Figure 5B and
Supplementary Figure S2A) (16). SREBP-1c is a bHLH-
leucine zipper protein that has dual DNA-binding speciﬁ-
city; it binds not only to the E-box, but also to the
SRE (14). EMSAs showed that GST-SREBP-1c binds to
SRE complex-containing oligonucleotides. Addition of
either Stra13 homodimer or HIF-1a/b heterodimer pre-
vented this binding (indicated by the higher arrow in
Figure 5A). Interestingly, both Stra13 homodimer and
HIF-1a/b heterodimer are able to interact with the SRE
complex (indicated by the lower arrowhead in Figure 5A).
In order to test whether the interactions between the
SREBP-1c promoter and Stra13 and HIF-1a/b are speciﬁc
for E-box sequences or SRE sequences, we added an
excess of unlabeled mutant oligonucleotides (Figure 5B).
Addition of unlabeled SRE mutant oligonucleotides more
eﬀectively diminished both Stra13 and HIF-1a/b binding
than addition of unlabeled E-box mutant oligonucleotides,
indicating that the Stra13 homodimer and HIF-1a/b
heterodimer interact with the SREBP-1c promoter,
E-box speciﬁcally (Figure 5B). Using the ChIP technique,
we conﬁrmed these ﬁndings in vivo. The transfected GST-
SREBP-1c was recruited to the endogenous chromosomal
SREBP-1c promoter, and cotransfection with either myc-
Stra13 or ﬂag-HIF-1a/HIF-1b prevented SREBP-1c from
binding to SREBP-1c promoter (Figure 5C). ChIP anal-
yses showed that both Stra13 homodimer and HIF-1a/b
heterodimer bound to the chromosomal promoter of their
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Figure 3. Involvement of Stra13 on the expression of SREBP-1c. (A) Hepa1c1c7 cells were incubated in hypoxic conditions (1% O2) for the indicated
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Figure 5. DNA-binding activity of SREBP-1c on the SREBP-1c promoter. (A) EMSAs were performed using the radiolabeled oligonucleotides for
the SREBP-1c promoter ( 89 to  53bp of mouse SREBP-1c gene) shown below. Recombinant GST-SREBP-1c protein was incubated with the
indicated amount of either Stra13- or HIF-1a/HIF-1b-programmed rabbit reticulocyte lysate, followed by incubation with radiolabeled oligonucleo-
tides. The upper arrow indicates the DNA–SREBP-1c complex, whereas the lower arrowhead indicates the DNA-Stra13 or DNA–HIF-1a/HIF-1b
complex. (B) For competition assays, the indicated amount of either Stra13- or HIF-1a/b-programmed rabbit reticulocyte lysate was incubated with
a 50-fold molar excess of either unlabeled SRE mutant oligonucleotides or E-box mutant oligonucleotides, followed by incubation with the
radiolabeled oligonucleotides containing the wild-type SREBP-1c promoter for 30min at 48C prior to loading. (C–G) pEBG-SREBP-1c was
transfected into 293 cells together with the indicated plasmids. Thereafter, ChIP assays were performed with the indicated antibodies as described
in Materials and methods section.
Nucleic Acids Research, 2008, Vol. 36, No. 20 6379target gene, Stra13 (the lowest panel in Figure 5D–F) (21).
Interestingly, the Stra13 homodimer is recruited to the
endogenous SREBP-1c promoter (the upper panel of
Figure 5D), whereas HIF-1a/b fails to do so (the upper
panel of Figure 5E). These ﬁndings suggest that HIF-1
induces Stra13, and that then Stra13 interacts with the
E-box sequence in the SREBP-1c promoter and/or with
the SREBP-1c protein itself, preventing SREBP-1c from
binding to its recognition site. We tested whether Stra13
directly interacts with E-box sequences in FAS promoter
by using EMSA (Supplementary Figure S2C) and ChIP
analyses (Figure 5F). We found that Stra13 fails to do so
(the upper panel of Figure 5F). Instead, the presence of
both Stra13 and HIF-1a/b prevents SREBP-1c from bind-
ing to the FAS promoter (Figure 5G and the middle panel
of Figure 5F). Our ﬁndings suggest that HIF-induced
Stra13 prevents SREBP-1c from binding to the FAS pro-
moter, not by competing for binding to E-box in FAS
promoter, but presumably by interacting with SREBP-1c
protein.
EffectsofStra13siRNAonhypoxicrepressionofSREBP-1c
In order to test the contribution of Stra13 to the hypoxic
repression of SREBP-1c and FAS, siRNA against Stra13/
DEC1 was transfected into Hepa1c1c7 cells. We noted
a reduction of about 50% in Stra13/DEC1 mRNA and
protein by two diﬀerent siRNAs (Figure 6A and Supple-
mentary Figure S3A). The results in Figure 6B and C
demonstrate that Stra13 siRNA failed to recover hypoxic
repression of FAS and SREBP-1c, suggesting that Stra13
is not unique repressor that mediates hypoxic repression
of SREBP-1c and FAS. DEC2, an isoform of Stra13/
DEC1 is identiﬁed in each mammalian species. Both
Stra13/DEC1 and DEC2 are induced by hypoxia. The
mRNA expression of Stra13/DEC1 gradually increased
and reached the maximum after 8-h exposure to hypoxia,
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Figure 6. Eﬀect of siRNA against Stra13/DEC1. (A–C) Hepa1c1c7 cells were transfected with the siRNAs against Stra13/DEC1 as described. Before
harvest, the transfected cells were exposed to hypoxia (1% O2, 24h). The levels of mRNA in each sample were quantiﬁed by Q-PCR. Values
represent means and standard deviations of three experiments. WB analysis was performed using anti-SREBP-1 antibody (Santa Cruz Biotechnology)
and anti-HDAC1 antibody. (D) Hepa1c1c7 cells were incubated in hypoxic conditions (1% O2) for the indicated times. The levels of Stra13/DEC1
and DEC2 mRNA were analyzed by Q-PCR. The expression level of 18S rRNA was used for normalization. (E) 3T3-L1 cells were transfected with
the siRNAs against Stra13/DEC1 as described. Before harvest, the transfected cells were exposed to hypoxia (1% O2, 24h). The level of DEC2
mRNA in each sample was quantiﬁed by Q-PCR. Values represent means and standard deviations of three experiments.
6380 Nucleic Acids Research, 2008, Vol. 36, No. 20while that of DEC2 instantly and temporarily increased
during acute hypoxic exposure (1–2h) (Figure 6D).
Li et al. (37) had showed that Stra13/DEC1 represses
the expression of DEC2 through binding to E-box in
DEC2 promoter. Consistently, we found that the induc-
tion of DEC2 is decreased as Stra13/DEC1 is gradually
increased (Figure 6D), and that the siRNA against Stra13
increases the expression of DEC2 (Figure 6E). We also
conﬁrmed that hypoxic induction of DEC2 also depends
on the HIF-1 (Supplementary Figure S3B and C) (21).
EffectofDEC2onhypoxicrepressionofSREBP-1candFAS
We investigated whether DEC2 also mediates the HIF-
dependent repression of FAS and SREBP-1c. We con-
ﬁrmed that overexpression of DEC2 reduced SREBP-1c
promoter activity, FAS promoter activity (Figure 7A and
Supplementary Figure S3D), and the expression level of
the endogenous SREBP-1c protein (Figure 7B). Similar to
Stra13, ChIP assay showed that DEC2 also interacts with
SREBP-1c (Figure 7C). ChIP analyses showed that DEC2
prevents GST-SREBP-1c from binding to the endogenous
SREBP-1c promoter (Figure 7D), and that DEC2
homodimer is able to bind SREBP-1c promoter (upper
panel) and Stra13 promoter (lower panel) through E-box
(Figure 7E) (38). Our results suggest that not only Stra13
but also DEC2 prevents SREBP-1c protein from binding
to its promoter by competing for binding to the E-box
and/or by interacting with SREBP-1c protein. We tested
whether siRNA against DEC2 can restore the hypoxic
repression of FAS and SREBP-1c. We noted a reduction
in DEC2 mRNA and protein by a siRNA against DEC2
(Figure 8A and Supplementary Figure S3E). The result in
Figure 8B and C showed that treatment of DEC2 siRNA
recovers the hypoxic repression of both FAS and SREBP-
1c. Accordingly, hypoxic repression of FAS and SREBP-
1c is regulated by both Stra13 and DEC2; however, DEC2
plays more pivotal role in hypoxic repression of SREBP-
1c and FAS (Figure 8D).
DISCUSSION
We have demonstrated that hypoxia represses the
FAS and SREBP-1c genes. SREBP-1c is a major transac-
tivator for several lipogenic enzymes, notably FAS. Since
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Figure 7. Eﬀect of DEC2 on the repression of SREBP-1c. (A) The mouse SREBP-1c promoter-driven reporter plasmid (250ng) and pCHO110
(50ng) was transfected into 5 10
4 NIH 3T3 cells together with 250ng of the indicated plasmid. The transfected cells were incubated in hypoxia
(1% O2, 16h) before harvesting, and luciferase assays were performed (26). Numbers represent averages and standard deviations of three indepen-
dent experiments. (B) NIH 3T3 cells were transfected with either pCMV-myc-Stra13 or pCMV-myc-DEC2. The transfected cells were incubated in
hypoxia (1% O2, 6h) before harvesting. Immunoblot analysis was performed using the indicated antibodies. (C) pEBG-SREBP-1c which encodes
GST-SREBP-1c was transfected into NIH 3T3 cells together with the indicated plasmids. The transfected cell lysates (300mg) were immunopreci-
pitated (IP) with resin-bound anti-myc antibody. And the resulting immunocomplexes or total lysates (30mg, 10% input) were analyzed by western
blotting. (D and E) pEBG-SREBP-1c was transfected into 293 cells together with the indicated plasmids. Thereafter, ChIP assays were performed
with the indicated antibodies as described in Materials and Methods section.
Nucleic Acids Research, 2008, Vol. 36, No. 20 6381SREBP-1c transactivates its own promoter, the initial
inhibition of SREBP-1c activity can trigger a positive
feedback loop of SREBP-1c repression. HIF represses
SREBP-1c by inducing Stra13/DEC1 and DEC2, bHLH
homodimeric transcription repressors. Both Stra13 and
DEC2 are also able to interact with other type of bHLH
protein, including SREBP-1c. We showed that both
Stra13 and DEC2 inhibit SREBP-1c-induced transcription
by competing for binding to the E-box in the SREBP-1c
promoter. In contrast to SREBP-1c promoter, Stra13 fails
to bind to E box in the FAS promoter. Nevertheless,
Stra13 prevents SREBP-1c from binding to FAS promoter
(Figure 5G) (39,40). This result implies that protein–
protein interaction between SREBP-1c and Stra13 also
prevent SREBP-1c from binding to its target promoter.
mRNA expression of DEC2 rapidly and temporarily
increased in acute hypoxia, while Stra13 increased in pro-
longed hypoxia (Figure 6D). These expression proﬁles
reﬂect the ﬁnding that Stra13 transcriptionally represses
DEC2 through binding to the E-box in the DEC2
promoter, thus maintained low level of DEC2 mRNA
in prolonged hypoxia (37,41). Transfection of siRNA
against Stra13 failed to reverse the hypoxic repression of
SREBP-1 and FAS, since knockdown of Stra13 increased
the expression of DEC2 even in prolonged hypoxia, then
DEC2 replaces Stra13 (Figure 6). In contrast, knockdown
of DEC2 by siRNA restored the hypoxic repression of
FAS and SREBP-1c, suggesting that DEC2 could be the
initiator of hypoxic repression of SREBP-1c whereas
Stra13 might maintain the event in prolonged hypoxia.
Therefore, without initial DEC2, late-started Stra13 fails
to eﬀectively repress the SREBP-1c and FAS genes in
response to hypoxia.
Supporting to this notion, this type of repressing action
of Stra13/DEC1 and DEC2 is also involved in the hypoxic
repression of DNA mismatch repair gene, MLH1. Forced
expression of both Stra13/DEC1 and DEC2 repressed
MLH1 expression. Knockdown of DEC2 by siRNA
recovered the hypoxic repression of the MHL1 but knock-
down of Stra13 by siRNA failed to do so, suggesting that
DEC2 repress MLH1 stronger than DEC1 does (41). The
functional diﬀerences between DEC1 and DEC2 are
not clear. DEC2, but not DEC1, represses cholesterol
7a-hydroxylase (CYP7A), and sterol 12a-hydroxylase
(CYP8B), presumably by binding to the E-boxes in their
promoters. Thereby DEC2, but not DEC1 controls the
circadian signals for bile acid synthesis (42).
Stra13/DEC1 and DEC2 are also involved in well-
known feed-forward regulation of circadian rhythm.
In mammals, the circadian clock is based on a cyclic
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Figure 8. Eﬀect of siRNA against DEC2. (A–C) 3T3-L1 cells were transfected with the siRNA against DEC2 as described. Before harvest, the
transfected cells were exposed to hypoxia (1% O2, 24h). The levels of DEC2 mRNA and FAS mRNA in each sample were quantiﬁed by Q-PCR.
Values represent means and standard deviations of three experiments. Immunoblot analysis was performed using anti-SREBP-1 antibody (Santa
Cruz Biotechnology). WB with anti-14-3-3g antibody was used as loading controls. (D) Schematic diagram: hypoxic repression of SREBP-1c and
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6382 Nucleic Acids Research, 2008, Vol. 36, No. 20feedback loop that includes Period (Per) and
Cryptochrome (Cry) proteins. Expression of Per and Cry
oscillates in phase with the day/night cycle. The Clock/
Bmal1 bHLH-PAS heterodimeric transcription factor
activates expression of Per and Cry genes by direct inter-
action with the E-boxes in their promoters. Expression
of the Stra13/DEC1 and DEC2 genes is also induced by
light (43). In turn, Stra13/DEC1 and DEC2 repress
Clock/Bmal1-induced Per and Cry transcription through
competition for the E-box and/or interaction with Bmal1
(44). Therefore, Stra13/DEC1 and DEC2 are involved in
resetting the circadian clock in response to light (45).
Expression of Stra13 and DEC2 in liver and fat tissues
showed a strong oscillatory trend, with a peak in the
light phase (46,47). In contrast both FAS and SREBP-1c
increase during the dark phase and fall during the light
phase (45,48). We showed above that Stra13 and DEC2
inhibit SREBP-1c in a similar manner to that in which
Stra13 and DEC2 inhibits Bmal1. Based on our ﬁndings
we can infer that Stra13 and DEC2 can be mediators that
control the oscillation of SREBP-1c and its target in
response to both light and hypoxia as a feed-forward
mechanism.
Regulation of SREBP-1c activity involves interactions
between bHLH proteins, and also between the E-box and
these proteins. Similarly, inhibitor of DNA binding (Id),
a dominant negative HLH protein, interacts with
SREBP-1c and prevents it from binding to the FAS pro-
moter (49). Upstream stimulatory factors (USF1/USF2
heterodimer), bHLH-leucine zipper transactivators, bind
to the E-box in the FAS promoter and mediate insulin
activation. Griﬃn et al. (50) showed that USF1 and
SREBP-1c interact in vivo and in vitro, and synergistically
activate the FAS promoter. Like USFs, the Stra13 and
DEC2 homodimer can interact with the E-box, and also
with SREBP-1c protein. However, in contrast to USF,
it prevents SREBP-1c from binding and activating the
target promoter. Interestingly, USF also interacts with
Stra13, so that they inhibit each other’s activity (51).
The ﬁndings that HIF is a master transcription factor
of several genes involved in glycolysis, angiogenesis
and metastasis, elucidate that HIF plays a pivotal role in
tumor progression. Beside of glycolysis, the cancer cells
also increase de novo synthesis of DNA, protein and
fatty acids which are required for the cell proliferation
(52,53). Treatment of tumor cells with FAS inhibitors
leads to cell cycle arrest and apoptosis, suggesting that
lipogenesis is essential for tumor progression (54).
Tumor-associated FAS and SREBP-1c are mainly induced
by a growth factor activated PI3/Akt signaling cascades
which are ampliﬁed through mutations in signaling mole-
cules such as PTEN, BCR-ABL, EGFR and HER2/neu
(53,55). Our ﬁnding that HIF rather inhibits the expres-
sion of FAS contradicts with the oncological implications
of HIF-a expression. However, the other important
ﬁndings provided clues that neither HIF nor hypoxia pro-
motes biosynthesis at the cellular level: (i) HIF-1 induces
pyruvate dehydrogenase kinase 1 which phosphorylates
and inhibits the pyruvate dehydrogenase, thereby limiting
entry of pyruvate into the TCA cycle and increasing the
conversion of pyruvate to lactate. This would prevent
biosynthesis which relies on the availability of TCA
cycle intermediates (2,4) and (ii) Lum et al. (56) showed
that in hematopoietic cells hypoxia increases glycolysis but
decreases lipid synthesis, and that reduction of HIF-1a
expression with RNA interference rather increases
lipid synthesis, cell size and rate of proliferation. In solid
tumor, a growth factor-activated PI3/Akt signaling cas-
cades trigger large increase in glycolysis, entry of carbon
into TCA cycle and lipogenesis, whereas HIF-1a increases
glycolysis but limits both the entry of pyruvate into TCA
cycle and lipogenesis, thus prevents oxidative stress and
ATP depletion (53,56). Although PI3/Akt/mTOR path-
way increases the translation of HIF-1a, the HIF-1a
does not gain the full transactivation activity, presumably
due to the hydroxylated asparagine residue in transactiva-
tion domain (57). Our results imply that malignant cancer
cells increase lipogenesis even in the presence of HIF-1a
not because HIF-a itself increases FAS expression,
but because the augmented PI3/Akt signaling cascades
exceed HIF signaling (58). Here, our results explain a
molecular mechanism by which the hypoxia-induced
HIF represses lipogenesis by repressing SREBP-1c and
FAS gene. By doing so, HIF reduces the ATP-consuming
anabolic process prior to the actual decrease of ATP
acting as feed-forward regulation.
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